September 2025 in “Clinical Cosmetic and Investigational Dermatology”
This analysis concluded that mesenchymal stem cell-derived exosome therapy may offer a promising and safe approach for hair restoration, especially in androgenetic alopecia, despite limitations in study consistency and size.
2 citations
,
March 2021 in “Journal of Cosmetic Dermatology”
This study found that human umbilical cord-derived mesenchymal stromal cell-conditioned media was safe and positively affected hairregeneration in 86.6% of participants in a pilot study.
30 citations
,
June 2017 in “Current stem cell research & therapy”
This review discusses the potential of adipose-derived stem cells for hairregeneration and suggests that these cells and their conditioned media may offer a promising strategy for treating hair loss.
Pelage Pharmaceuticals announced positive Phase 2a trial results for PP405 in hair loss therapy. The conversation discusses the delay in publishing full results and the need for further trials and approvals.
A stem cell and adenosine triphosphate cocktail showed promising results in hair regrowth for male and female mice, with potential for future clinical trials. Users humorously reacted to the success in mice, expressing hope for human application.
Hair follicle regenerative therapy is being developed, with clinical trials planned in Japan, potentially allowing for hair cloning and eliminating the need for treatments like finasteride. If successful, the treatment could be available in Japan by 2025, but widespread access and affordability may take longer.
Topical Metformin shows potential for regeneratinghair follicles and minimizing scarring in hair transplant donor areas, similar to Verteporfin but without its side effects. The discussion suggests considering Metformin for post-hair transplant care, though more human trials are needed.
A potential non-invasive topical treatment targeting the WNT Signaling Pathway for hairregeneration is being researched, with positive results on human hair follicle cells. Current effective treatments for hair loss include Minoxidil, finasteride, and hair transplantation.
What do clinical trials say about the safety and effectiveness of SCUBE3 for hair regrowth?No clinical trial of SCUBE3 for hair regrowth has been registered on ClinicalTrials.gov or published, so there is no human safety or effectiveness data. The evidence is limited to one 2022 laboratory and mouse study reporting that SCUBE3 activates hair follicle stem cells through TGF-beta signalling.
Are there any clinical studies supporting follistatin as a hair loss treatment?There is no controlled human trial showing follistatin treats hair loss; the published work is mouse and laboratory biology on the activin/follistatin signalling system, plus one small 2011 phase 1 injection study of a combination product, so follistatin remains experimental and unapproved.